Preprint Review Version 4 Preserved in Portico This version is not peer-reviewed

Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders

Version 1 : Received: 13 April 2023 / Approved: 13 April 2023 / Online: 13 April 2023 (03:49:28 CEST)
Version 2 : Received: 13 April 2023 / Approved: 13 April 2023 / Online: 13 April 2023 (07:05:41 CEST)
Version 3 : Received: 13 April 2023 / Approved: 13 April 2023 / Online: 13 April 2023 (08:57:13 CEST)
Version 4 : Received: 13 April 2023 / Approved: 14 April 2023 / Online: 14 April 2023 (03:34:06 CEST)

A peer-reviewed article of this Preprint also exists.

Tsuchiya, H. Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders. Dent. J. 2023, 11, 140. Tsuchiya, H. Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders. Dent. J. 2023, 11, 140.

Abstract

Since the worldwide spread of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), treating taste and saliva secretory disorders associated with coronavirus disease 2019 (COVID-19) has become one of the most critical issues in the COVID-19 era. The aim of the present study was to update information on treatments being applicable to such oral symptoms and discuss their pathogenic mechanisms. Promising treatments include different types of methods using tetracycline, corticosteroid, zinc, stellate ganglion block, phytochemical curcumin, traditional herbal medicine, nutraceutical vitamin D, photobiomodulation, antiviral drug, malic acid sialagogue, chewing gum, acupuncture, and/or moxibustion. At present, however, fully validated treatments are still lacking for COVID-19-associated ageusia/dysgeusia/hypogeusia and xerostomia/dry mouth/hyposalivation. An appropriately selected treatment and oral healthcare should be provided to COVID-19 patients and survivors suffering from taste and saliva secretory disorders. Understanding of currently available treatment options is required for dental profes-sionals because they not only experience patients who were infected with SARS-CoV-2 or recov-ered from COVID-19 but first become aware of their abnormal taste and salivary secretion. By doing so, dentists and dental hygienists can play a crucial role in managing COVID-19-associated oral symptoms and contribute to improving the oral health-related quality of life of the relevant dental patients.

Keywords

COVID-19; taste disorder; saliva secretory disorder; treatment; pathogenic mechanism

Subject

Medicine and Pharmacology, Dentistry and Oral Surgery

Comments (1)

Comment 1
Received: 14 April 2023
Commenter: Hironori Tsuchiya
Commenter's Conflict of Interests: Author
Comment: Unnecessary repetition in Table 2 (page 15) was deleted.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.